AMSF vs GAIN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AMSF exhibits significant fundamental weakness, highlighted by a Piotroski F-Score of 3/9, indicating poor financial health. The stock is currently trading at $30.74, which is a premium to both its Graham Number ($27.06) and its growth-based Intrinsic Value ($17.01). While revenue growth remains positive, earnings are declining (-8.50% YoY) and the company has failed to beat earnings estimates in the last four consecutive quarters. This fundamental deterioration is mirrored by a 0/100 technical trend and bearish insider activity from the CFO.
GAIN presents a stark contrast between deep value and deteriorating fundamental health, highlighted by a weak Piotroski F-Score of 2/9. While the stock trades at a significant discount to its Graham Number ($32.61) and Intrinsic Value ($93.22), this valuation is offset by a catastrophic recent earnings trend, including a -633.3% YoY EPS growth. The company maintains a strong dividend yield and ROE, but a critical liquidity risk is evident in the 0.18 current ratio. Overall, the asset is undervalued on a book basis but exhibits high operational risk.
Compare Another Pair
Related Comparisons
AMSF vs GAIN: Head-to-Head Comparison
This page compares AMERISAFE, Inc. (AMSF) and Gladstone Investment Corporation (GAIN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.